If you have been reading about synthetic peptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-02. Numbers and descriptions here follow the published literature rather than marketing material.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
=== Worms === The microscopic soil-dwelling nematode roundworms Panagrolaimus detritophagus and Plectus parvus are the only eukaryotic organisms that have been proven to be viable after cryopreservation for many years (30,000 to 40,000 years). In this case, the preservation was natural rather than artificial, due to permafrost. They came alive when warmed up.
Foreign visitors whose fingerprints are registered on arrival may use the eIACS lanes for exit clearance. In addition, the Biometric Identification of Motorbikers (BIKES) System is available for eligible motorcyclists at the land border crossings with Malaysia. Meanwhile, all visitors who have been fingerprinted on entry at a manned counter can use the eIACS to leave Singapore by air. Additionally, nationals of certain countries may register to use the eIACS system on entry, provided they meet prescribed conditions. South Korea: South Korea maintains a programme known as the Smart Entry Service, open for registration by South Koreans aged 7 or above and by registered foreigners aged 17 or above. Furthermore, visitors aged 17 or older may use the Smart Entry Service on exit at international airports, as long as they have provided their biometrics on arrival. Taiwan: An automated entry system, eGate, exists in areas administered by the Republic of China, providing expedited border control for ROC nationals as well as certain classes of residents and frequent visitors. Users scan their travel documents at the gate and are passed through for facial recognition. As of 2019, there have been instances of foreign non-registered travellers allowed to use the e-Gate system to depart, notably at Taipei Taoyuan Airport Terminal 1, but not Terminal 2, using a passport scan and fingerprints. Thailand: The automated passport control (APC) system, which uses a facial recognition system, has been available for Thai nationals since 2012, and more than 20 million have used it.
phenome The complete set of phenotypes that are or can be expressed by a genome, cell, tissue, organism, or species; the sum of all of its manifest chemical, morphological, and behavioral characteristics or traits.
=== Synthesis from elemental mercury === Metallic mercury reacts only slowly with methyl iodide to give dimethylmercury. With more electrophilic alkylating agents, the reaction is more efficient. Also, sodium amalgams react with organic halides to give diorganomercury compounds.
== Awards and honors == 1976–1981 - N.I.H. Research Career Development Award 1975, 1992 - Kaiser Permanente Award for Excellence in Teaching 1996–1997 - President, Biophysical Society 1997 - Distinguished Lecturer, Beckman Center, University of Illinois at Urbana-Champaign 1999 - Distinguished Service Award, Biophysical Society 2000 - Athalie Clarke Research Achievement Award, Outstanding Researcher, UCI College of Medicine 2001 - Fellow, Biophysical Society 2002 - César Milstein Plenary Lecture, XIVth International Biophysics Congress 2006 - Keynote Lecture, Gordon Research Conference on Biopolymers 2008 - Ph.D. honoris causa, Stockholm University 2009 - Avanti Award in Lipids, Biophysical Society 2009 - Bioengineering Distinguished Speaker, University of California at Riverside 2010 - Matrone Distinguished Lecture in Biochemistry, North Carolina State University 2010 - Cátedra de Investigación Científica, Autonomous University of San Luis Potosí 2010 - Frederic M. Richards Lecture, Yale 2011 - O'Malley Lectures in Chemical Biology, Boston College 2014 - Carl Brändén Award, The Protein Society 2016 - Fellow, Neutron Scattering Society of America 2018 - Fellow, American Association for the Advancement of Science 2019 - University of Kansas Newmark Award Lecture 2022 - UCI School of Medicine, Lifetime Research Achievement Award for Excellence in Basic Science research.
Sources: en.wikipedia.org
==== Campaign coordinator's death ==== On 17 October 2016, during his campaign for the second round, the executive-coordinator of Melo's campaign, Plínio Zalewski, was found dead at the PMDB's base of operations in the Centro Histórico neighborhood. He was one of the campaign's principal spokespersons, and would be eulogized by Melo in the wake of his death. He was buried the following day. The main hypothesis is that he died by suicide with a cold weapon. At the place where he died, a suicide letter was found. The PMDB temporarily suspended the campaign for 24 hours.
Lethal injection dosage: 2–5 grams Sodium thiopental (US trade name: Sodium Pentothal) is an ultra-short-acting barbiturate, often used for anesthesia induction and for medically induced coma. The typical anesthesia induction dose is 0.35 grams. Loss of consciousness is induced within 30–45 seconds at the typical dose, while a 5 gram dose (14 times the normal dose) is likely to induce unconsciousness in 10 seconds. A full medical dose of thiopental reaches the brain in about 30 seconds. This induces an unconscious state. Five to twenty minutes after injection, approximately 15% of the drug is in the brain, with the rest in other parts of the body. The half-life of this drug is about 11.5 hours, and the concentration in the brain remains at around 5–10% of the total dose during that time. When a 'mega-dose' is administered, as in state-sanctioned lethal injection, the concentration in the brain during the tail phase of the distribution remains higher than the peak concentration found in the induction dose for anesthesia, because repeated doses—or a single very high dose as in lethal injection—accumulate in high concentrations in body fat, from which the thiopental is gradually released. This is the reason why an ultra-short acting barbiturate, such as thiopental, can be used for long-term induction of medical coma. Historically, thiopental has been one of the most commonly used and studied drugs for the induction of coma. Protocols vary for how it is given, but the typical doses are anywhere from 500 mg up to 1.5 grams.
Red meat consumption is associated with an increased risk of coronary heart disease, high blood pressure and stroke. Factors associated with increased stroke risk from consuming red meat include saturated fats that increase levels of blood cholesterol, LDL cholesterol, triglycerides, and heme iron, which may precipitate atherogenesis in cerebral arteries, leading to stroke. While it was thought that saturated fat was to blame, more recent research indicates that atherosclerosis is largely mediated by trimethylamine N-oxide (TMAO). This is produced by gut bacteria from compounds such as choline and carnitine in the meat. TMAO is also associated with colorectal cancer. In 2020, the National Heart Foundation of New Zealand Expert Nutrition Policy (ENP) issued a position statement that concluded that high consumption of red meat increases risk of heart disease and stroke by 16%.
Women have served on US Navy surface ships since 1993, and as of 2011–2012, began serving on submarines for the first time. Until presently, the Navy allowed only three exceptions to women being on board military submarines: female civilian technicians for a few days at most, women midshipmen on an overnight during summer training for Navy ROTC and Naval Academy, and family members for one-day dependent cruises. In 2009, senior officials, including then-Secretary of the Navy Ray Mabus, Joint Chief of Staff Admiral Michael Mullen, and Chief of Naval Operations Admiral Gary Roughead, began the process of finding a way to implement women on submarines. The US Navy rescinded its "no women on subs" policy in 2010. Both the US and British navies operate nuclear-powered submarines that deploy for periods of six months or longer. Other navies that permit women to serve on submarines operate conventionally powered submarines, which deploy for much shorter periods—usually only for a few months. Prior to the change by the US, no nation using nuclear submarines permitted women to serve on board. In 2011, the first class of female submarine officers graduated from Naval Submarine School's Submarine Officer Basic Course (SOBC) at the Naval Submarine Base New London. Additionally, more senior ranking and experienced female supply officers from the surface warfare specialty attended SOBC as well, proceeding to fleet Ballistic Missile (SSBN) and Guided Missile (SSGN) submarines along with the new female submarine line officers beginning in late 2011.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.